HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

238Pu: a review of the biokinetics, dosimetry, and implications for human exposures.

Abstract
Plutonium-238 (238Pu) has a half-life of about 87.7 y and thus a higher specific activity than 239Pu. It is used in radioisotope thermoelectric generators and is a substantial source of plutonium alpha-radiation in spent nuclear fuels. Early animal studies demonstrated differences in the biokinetics of inhaled oxides of 238Pu and 239Pu with 238Pu having a substantially more rapid translocation from the lungs to the systemic organs, particularly the skeleton. This resulted in the predominant occurrence of skeletal cancers in animals exposed to 238Pu oxides but lung cancers in those with exposures to 239Pu oxides. The anatomical distribution of osteogenic sarcomas seen in animal studies was similar to that observed with 239Pu and also in plutonium workers but differed from naturally occurring tumors. The in vivo "solubility" of 238Pu has been associated with the relative amounts of 238Pu/239Pu in the particles and calcination temperatures during the preparation of the dioxides. There is experimental evidence of in vivo 238Pu particle fragmentation attributed to nuclear recoil during radioactive decay. The resulting conversion of microparticles to nanoparticles may alter their interactions with macrophages and transport across epithelial barriers. There are few documented cases of human exposures, but the biokinetics appeared to depend on the chemical and physical nature of the aerosols. Robust human biokinetic and dosimetric models have not been developed, due in part to the lack of data. With the acceleration of nuclear technologies and the greater demand for reprocessing and/or disposal of spent nuclear fuels, the potential for human exposure to 238Pu will likely increase in the future.
AuthorsKlara G Suslova, Valentin F Khokhryakov, Alexandra B Sokolova, Scott C Miller
JournalHealth physics (Health Phys) Vol. 102 Issue 3 Pg. 251-62 (Mar 2012) ISSN: 1538-5159 [Electronic] United States
PMID22420017 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Review)
Chemical References
  • Aerosols
  • plutonium dioxide
  • Plutonium
Topics
  • Aerosols
  • Animals
  • Bone Neoplasms (etiology)
  • Endocytosis
  • Health Physics
  • Humans
  • Intestinal Absorption
  • Lung (metabolism, radiation effects)
  • Neoplasms, Radiation-Induced (etiology)
  • Nuclear Reactors
  • Occupational Exposure
  • Osteosarcoma (etiology)
  • Plutonium (administration & dosage, pharmacokinetics, toxicity)
  • Radiometry

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: